Insider Selling: Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) General Counsel Sells 3,341 Shares of Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) General Counsel Bryan Wahl sold 3,341 shares of the firm’s stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $46.29, for a total value of $154,654.89. Following the completion of the sale, the general counsel now directly owns 58,057 shares in the company, valued at approximately $2,687,458.53. The trade was a 5.44 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Bryan Wahl also recently made the following trade(s):

• On Thursday, March 20th, Bryan Wahl sold 3,084 shares of Tarsus Pharmaceuticals stock. The stock was sold at an average price of $50.11, for a total transaction of $154,539.24.

Tarsus Pharmaceuticals Stock Up 0.1 %

TARS opened at $49.97 on Friday. Tarsus Pharmaceuticals, Inc. has a 12 month low of $20.08 and a 12 month high of $57.28. The company has a current ratio of 5.42, a quick ratio of 5.38 and a debt-to-equity ratio of 0.30. The business’s 50-day moving average price is $48.48 and its 200-day moving average price is $45.21. The company has a market cap of $1.92 billion, a P/E ratio of -13.12 and a beta of 1.05.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its quarterly earnings results on Tuesday, February 25th. The company reported ($0.60) EPS for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. The business had revenue of $66.41 million for the quarter, compared to analysts’ expectations of $58.80 million. On average, equities analysts expect that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Jefferies Financial Group increased their price target on shares of Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the stock a “buy” rating in a report on Thursday, March 6th. HC Wainwright restated a “buy” rating and set a $73.00 price target on shares of Tarsus Pharmaceuticals in a research report on Wednesday, February 26th. Guggenheim reaffirmed a “buy” rating and set a $78.00 price target (up previously from $75.00) on shares of Tarsus Pharmaceuticals in a research note on Monday, February 24th. Barclays reduced their price objective on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 26th. Finally, Oppenheimer upped their target price on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 22nd. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $63.67.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TARS. Crowley Wealth Management Inc. bought a new stake in Tarsus Pharmaceuticals in the 4th quarter worth $25,000. GF Fund Management CO. LTD. purchased a new stake in shares of Tarsus Pharmaceuticals during the fourth quarter worth about $44,000. R Squared Ltd purchased a new stake in shares of Tarsus Pharmaceuticals during the fourth quarter worth about $53,000. FMR LLC grew its stake in shares of Tarsus Pharmaceuticals by 236.6% in the third quarter. FMR LLC now owns 5,032 shares of the company’s stock worth $166,000 after purchasing an additional 3,537 shares during the last quarter. Finally, Quarry LP purchased a new position in Tarsus Pharmaceuticals during the 4th quarter valued at about $166,000. 90.01% of the stock is currently owned by institutional investors.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.